Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

NCT04796857 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-GCB/ABC Diffuse Large B-Cell Lymphoma
High-grade B-cell Lymphoma
Follicular Lymphoma Grade IIIb
Transformed Lymphoma
EBV-Positive DLBCL, Nos
ALK-Positive Anaplastic Large Cell Lymphoma

Interventions

DRUG: PD-1 Antibody
DRUG: Lenalidomide

Sponsor

Huiqiang Huang